Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Clinical Management and Treatment of Orthopedic Oncology: 2nd Edition
share announcement

Clinical Management and Treatment of Orthopedic Oncology: 2nd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Orthopedics".

Deadline for manuscript submissions: 28 September 2025 | Viewed by 632

Special Issue Editors

Dr. Muhammad Umar Jawad

E-Mail Website
Guest Editor
Department of Orthopedic Surgery, Banner University of Arizona College of Medicine, Phoenix, AZ, USA
Interests: orthopedic oncology; sarcoma biology; sarcoma epidemiology
Special Issues, Collections and Topics in MDPI journals
Dr. Danielle Elizabeth Greig

E-Mail Website
Guest Editor Assistant
Department of Orthopaedic Surgery, University of California, Los Angeles, Santa Monica, CA, USA
Interests: orthopedic oncology; sarcoma; implant science; metastatic bone disease

Special Issue Information

Dear Colleagues,

Orthopedic oncology is a diverse field of medicine that deals with various oncologic processes affecting the musculoskeletal system. These include benign connective tissue neoplasms, metastatic disease and primary bone and soft tissue sarcomas. Recent laboratory and epidemiological evidence has implicated the role of the bone micro-environment in the development of widespread metastatic disease. Multidisciplinary discussion and care, in which orthopedic oncology plays a leading role, is critical for optimizing the outcomes for these rare diseases. Multimodal treatment strategies, including local treatment modalities such as surgery, percutaneous ablative procedures and radiotherapy, and systemic modalities such as chemo- and immuno-therapy in adjuvant and neoadjuvant settings, are being employed. The current Special Issue aims to address the novel developments in some of the key areas of treatment strategies employed in the field of orthopedic oncology.

Dr. Muhammad Umar Jawad
Guest Editor

Dr. Danielle Elizabeth Greig
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bone metastasis
  • primary bone tumors
  • soft tissue sarcoma
  • limb salvage
  • multimodal treatment strategies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 443 KiB  
Article
A Multicenter Study by the DENO Research Group on the Use of Denosumab in Giant-Cell Tumors of the Bone
by DENO Research Group, Carolina de la Calva, Manuel Angulo, Paula González-Rojo, Ana Peiró, Pau Machado, Juan Luis Cebrián, Roberto García-Maroto, Antonio Valcárcel, Pablo Puertas, Gregorio Valero-Cifuentes, Óscar Pablos, Miriam Maireles, María Luisa Fontalva, Iván Chaves, Aida Orce, Luis Coll-Mesa, Israel Pérez, Fausto González, María del Carmen Sanz and Isidro Graciaadd Show full author list remove Hide full author list
J. Clin. Med. 2025, 14(9), 3242; https://doi.org/10.3390/jcm14093242 - 7 May 2025
Abstract
Background/Objectives: Despite the therapeutic potential of denosumab for the treatment of giant-cell tumors of the bone (GCTBs), there is a lack of standardization in treatment protocols. Methods: We present a multicenter, retrospective, descriptive study conducted across the seven hospitals in Spain [...] Read more.
Background/Objectives: Despite the therapeutic potential of denosumab for the treatment of giant-cell tumors of the bone (GCTBs), there is a lack of standardization in treatment protocols. Methods: We present a multicenter, retrospective, descriptive study conducted across the seven hospitals in Spain affiliated with the DENO Research Group. Seventy-three patients diagnosed with GCTB and treated with denosumab were included and stratified according to treatment strategy—neoadjuvant (n = 38), adjuvant (n = 8), and single treatment (n = 27). Results: Patients in the neoadjuvant group received denosumab for a median of 6.1 months, with reintroduction after surgery in 25.8% of all cases. Among the neoadjuvant patients treated with curettage, recurrence was 35.5%, with no association with denosumab treatment duration (p = 0.274) nor with denosumab reintroduction after surgery (p = 0.405). In the adjuvant group, those who completed treatment received denosumab for 15.3 months, while those still undergoing therapy received it for a median of 12.8 months; only one case (12.5%) recurred. Recurrence rates in neoadjuvant and adjuvant treatment strategies were not different (p = 0.394). Patients treated only with denosumab and no longer on treatment had received it for 34.2 months, with 31.3% recurrence; those still on treatment had received it for 51.8 months, with 25.0% recurrence. Across all strategies, more than 85% of patients reported favorable clinical outcomes, and only 43.8% presented adverse events. No deaths occurred during this study. Conclusions: Although patients who experienced recurrence during neoadjuvant treatment had longer durations of denosumab administration, the difference was not statistically significant. Similarly, recurrence rates did not differ significantly, whether denosumab was reintroduced after surgery or not. Among the patients treated with curettage, recurrence rates were comparable between neoadjuvant and adjuvant strategies. Discontinuation of the single treatment did not necessarily result in disease progression. Full article
(This article belongs to the Special Issue Clinical Management and Treatment of Orthopedic Oncology: 2nd Edition)
►▼ Show Figures

Figure 1

13 pages, 8205 KiB  
Article
Fixation with Carbon Fiber Plates After Curettage in Benign and Locally Aggressive Bone Tumors: Clinical and Radiographic Outcomes
by Edoardo Ipponi, Elena Bechini, Vittoria Bettarini, Martina Cordoni, Fabrizia Gentili, Antonio D’Arienzo, Paolo Domenico Parchi and Lorenzo Andreani
J. Clin. Med. 2025, 14(7), 2371; https://doi.org/10.3390/jcm14072371 - 29 Mar 2025
Viewed by 306
Abstract
Background: Curettage represents a reliable therapeutic option for large-sized benign and locally aggressive bone tumors. In cases of impending fractures, internal fixation with plates and screws can be necessary to stabilize the treated bone after curettage. Metal plates have been the only [...] Read more.
Background: Curettage represents a reliable therapeutic option for large-sized benign and locally aggressive bone tumors. In cases of impending fractures, internal fixation with plates and screws can be necessary to stabilize the treated bone after curettage. Metal plates have been the only fixation devices available on the market for decades, but Carbon-fiber-reinforced polyetheretherketone (CFR-PEEK) now represents an alternative in orthopedic oncology. Methods: We reviewed our patients with benign or locally aggressive bone tumors treated with curettage and fixation with CFR-PEEK plates. Plate length and curettage technique were chosen considering the characteristics of each lesion. We recorded the size and location of the lesions, adjuvant treatments and fillers used after curettage, complications, and local recurrences. Postoperative functionality was assessed using the MSTS score. Results: Forty cases were included in our study. The tumors were located in the distal femur (19 cases), femur shaft (1), humerus (17), or proximal tibia (3). Local adjuvants were used in 20 cases. Cavities were filled with bone allografts in 30 cases and cement in 10 cases. Only four cases suffered postoperative complications, and two developed local recurrences. The mean postoperative follow-up was 29.2 months. The mean postoperative upper and lower limb MSTS was 28.0 and 26.7, respectively. Conclusions: After an accurate curettage and an adequate filling of the resulting bone gap, CFR-PEEK plates can provide good mechanical resistance, and their radio-transparency can ease the early diagnosis of local recurrences. CFR-PEEK plates should be considered in selected cases, in a personalized surgical approach. Full article
(This article belongs to the Special Issue Clinical Management and Treatment of Orthopedic Oncology: 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop